Patents by Inventor Stanley N. Cohen
Stanley N. Cohen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9737480Abstract: The invention provide isolated arrestin domain-containing protein 1 (ARRDC1)-mediated micro vesicles (ARMMs). Methods for generating and for isolating ARMMs are also provided herein. ARMMs can be used to deliver agents, for example, nucleic acids (e.g., siRNAs, microRNAs, lincRNAs), proteins (e.g., transcription factors, chromatin modulators, kinases, phosphorylases, or recombinases), or small molecules to target cells in vitro and in vivo, and methods for such ARMM-mediated delivery are provided herein. Diagnostic and therapeutic methods using ARMMs are also described herein.Type: GrantFiled: February 6, 2013Date of Patent: August 22, 2017Assignees: President and Fellows of Harvard College, The Board of Trustees of the Leland Standford Junior UniversityInventors: Quan Lu, Joseph F. Nabhan, Stanley N. Cohen
-
Patent number: 9637741Abstract: This invention provides a method for modulating the expression of a first gene in a cell wherein the first gene is one containing more than 36 CAG trinucleotide repeats and encoding a protein that form polyglutamine-mediated protein aggregation. Suppression of the first gene is achieved by reducing the expression of SPT4 gene or SUPT4H gene. It can also be achieved by inhibiting the formation of a Spt4/Spt5 complex or a Supt4h/Supt5h complex. Also provided is a method for identifying an agent useful for modulating the expression and aggregation of CAG-expanded gene product, or treating a polyglutamine disease such as Huntington's disease.Type: GrantFiled: December 2, 2015Date of Patent: May 2, 2017Assignees: National Yang Ming University, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Tzu-Hao Cheng, Chia-Rung Liu, Tzu-Han Wang, Stanley N. Cohen
-
Publication number: 20160206566Abstract: Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.Type: ApplicationFiled: October 30, 2015Publication date: July 21, 2016Applicants: President and Fellows of Harvard College, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Quan Lu, Qiyu Wang, Stanley N. Cohen
-
Publication number: 20160152978Abstract: Aspects of the invention include methods of selectively reducing the deleterious activity of mutant extended trinucleotide repeat containing genes in a cell, as well as compositions used in such methods. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended trinucleotide repeat containing gene may be selectively reduced in a variety of different ways, e.g., by selectively decreasing SPT4 mediated transcriptional activity, by enhancing functionality of proteins encoded thereby, etc. Aspects of the invention further include assays for identifying agents that find use in methods of the invention, e.g. as summarized above. Methods and compositions of the invention find use in a variety of different applications, including the prevention or treatment of disease conditions associated with the presence of genes containing mutant extended trinucleotide repeats, such as Huntington's Disease (HD).Type: ApplicationFiled: December 7, 2015Publication date: June 2, 2016Inventors: Tzu-Hao Cheng, Chia-Rung Liu, Tzu-Han Wang, Stanley N. Cohen
-
Publication number: 20160116456Abstract: This invention provides a method for modulating the expression of a first gene in a cell wherein the first gene is one containing more than 36 CAG trinucleotide repeats and encoding a protein that form polyglutamine-mediated protein aggregation. Suppression of the first gene is achieved by reducing the expression of SPT4 gene or SUPT4H gene. It can also be achieved by inhibiting the formation of a Spt4/Spt5 complex or a Supt4h/Supt5h complex. Also provided is a method for identifying an agent useful for modulating the expression and aggregation of CAG-expanded gene product, or treating a polyglutamine disease such as Huntington's disease.Type: ApplicationFiled: December 2, 2015Publication date: April 28, 2016Inventors: Tzu-Hao Cheng, Chia-Rung Liu, Tzu-Han Wang, Stanley N. Cohen
-
Patent number: 9226935Abstract: This invention provides a method for modulating the expression of a first gene in a cell wherein the first gene is one containing more than 36 CAG trinucleotide repeats and encoding a protein that form polyglutamine-mediated protein aggregation. Suppression of the first gene is achieved by reducing the expression of SPT4 gene or SUPT4H gene. It can also be achieved by inhibiting the formation of a Spt4/Spt5 complex or a Supt4h/Supt5h complex. Also provided is a method for identifying an agent useful for modulating the expression and aggregation of CAG-expanded gene product, or treating a polyglutamine disease such as Huntington's disease.Type: GrantFiled: July 8, 2013Date of Patent: January 5, 2016Assignees: NATIONAL YANG MING UNIVERSITY, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Tzu-Hao Cheng, Chia-Rung Lu, Tzu-Han Wang, Stanley N. Cohen
-
Patent number: 9211303Abstract: Aspects of the invention include methods of selectively reducing the deleterious activity of mutant extended trinucleotide repeat containing genes in a cell, as well as compositions used in such methods. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended trinucleotide repeat containing gene may be selectively reduced in a variety of different ways, e.g., by selectively decreasing SPT4 mediated transcriptional activity, by enhancing functionality of proteins encoded thereby, etc. Aspects of the invention further include assays for identifying agents that find use in methods of the invention, e.g. as summarized above. Methods and compositions of the invention find use in a variety of different applications, including the prevention or treatment of disease conditions associated with the presence of genes containing mutant extended trinucleotide repeats, such as Huntington's Disease (HD).Type: GrantFiled: December 8, 2011Date of Patent: December 15, 2015Assignees: National Yang-Ming University, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Tzu-Hao Cheng, Chia-Rung Liu, Tzu-Han Wang, Stanley N. Cohen
-
Publication number: 20150037421Abstract: The invention provide isolated arrestin domain-containing protein 1 (ARRDC1)-mediated micro vesicles (ARMMs). Methods for generating and for isolating ARMMs are also provided herein. ARMMs can be used to deliver agents, for example, nucleic acids (e.g., siRNAs, microRNAs, lincRNAs), proteins (e.g., transcription factors, chromatin modulators, kinases, phosphorylases, or recombinases), or small molecules to target cells in vitro and in vivo, and methods for such ARMM-mediated delivery are provided herein. Diagnostic and therapeutic methods using ARMMs are also described herein.Type: ApplicationFiled: February 6, 2013Publication date: February 5, 2015Applicants: President and Fellows of Harvard College, The Board of Trustees of the Leland Stanford JuniorUniversityInventors: Quan Lu, Joseph F. Nabhan, Stanley N. Cohen
-
Patent number: 8691780Abstract: Methods and compositions for enhancing taxane sensitivity are provided. Aspects of the subject methods include administering to a subject a txr1 pathway modulatory agent in conjunction with a taxane. Also provided are txr1 polypeptides and nucleic acids encoding the same. The subject methods and compositions find use in a variety of different applications.Type: GrantFiled: February 16, 2006Date of Patent: April 8, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Chih Jian Lih, Stanley N. Cohen
-
Publication number: 20130331437Abstract: This invention provides a method for modulating the expression of a first gene in a cell wherein the first gene is one containing more than 36 CAG trinucleotide repeats and encoding a protein that form polyglutamine-mediated protein aggregation. Suppression of the first gene is achieved by reducing the expression of SPT4 gene or SUPT4H gene. It can also be achieved by inhibiting the formation of a Spt4/Spt5 complex or a Supt4h/Supt5h complex. Also provided is a method for identifying an agent useful for modulating the expression and aggregation of CAG-expanded gene product, or treating a polyglutamine disease such as Huntington's disease.Type: ApplicationFiled: July 8, 2013Publication date: December 12, 2013Applicant: National Yang Ming UniversityInventors: Tzu-Hao CHENG, Chia-Rung Liu, Tzu-Han Wang, Stanley N. Cohen
-
Publication number: 20130317088Abstract: Aspects of the invention include methods of selectively reducing the deleterious activity of mutant extended trinucleotide repeat containing genes in a cell, as well as compositions used in such methods. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended trinucleotide repeat containing gene may be selectively reduced in a variety of different ways, e.g., by selectively decreasing SPT4 mediated transcriptional activity, by enhancing functionality of proteins encoded thereby, etc. Aspects of the invention further include assays for identifying agents that find use in methods of the invention, e.g. as summarized above. Methods and compositions of the invention find use in a variety of different applications, including the prevention or treatment of disease conditions associated with the presence of genes containing mutant extended trinucleotide repeats, such as Huntington's Disease (HD).Type: ApplicationFiled: December 8, 2011Publication date: November 28, 2013Applicants: The Board of Trustees of the Leland Stanford Junior University, NATIONAL YANG-MING UNIVERSITYInventors: Tzu-Hao Cheng, Chia-Rung Liu, Tzu-Han Wang, Stanley N. Cohen
-
Patent number: 8569254Abstract: This invention provides a method for modulating the expression of a first gene in a cell wherein the first gene is one containing more than 36 CAG trinucleotide repeats and encoding a protein that form polyglutamine-mediated protein aggregation. Suppression of the first gene is achieved by reducing the expression of SPT4 gene or SUPT4H gene. It can also be achieved by inhibiting the formation of a Spt4/Spt5 complex or a Supt4h/Supt5h complex. Also provided is a method for identifying an agent useful for modulating the expression and aggregation of CAG-expanded gene product, or treating a polyglutamine disease such as Huntington's disease.Type: GrantFiled: May 18, 2011Date of Patent: October 29, 2013Assignee: National Yang Ming UniversityInventors: Tzu-Hao Cheng, Chia-Rung Lu, Tzu-Han Wang, Stanley N. Cohen
-
Patent number: 8404807Abstract: TSG101 is a tumor susceptibility gene whose homozygous functional knock out in fibroblasts leads to transformation and the ability of these cells to form metastatic tumors in nude mice. The cellular transformation that results from inactivation of TSG101 is reversible by restoration of TSG101 function. Decreased expression of TSG101 is associated with the occurrence of certain human cancers, including breast carcinomas. The TSG101 nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as treatment of cancer, identification of cell type based on expression, and the like.Type: GrantFiled: May 26, 2011Date of Patent: March 26, 2013Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Stanley N. Cohen, Limin Li
-
Publication number: 20110251376Abstract: TSG101 is a tumor susceptibility gene whose homozygous functional knock out in fibroblasts leads to transformation and the ability of these cells to form metastatic tumors in nude mice. The cellular transformation that results from inactivation of TSG101 is reversible by restoration of TSG101 function. Decreased expression of TSG101 is associated with the occurrence of certain human cancers, including breast carcinomas. The TSG101 nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as treatment of cancer, identification of cell type based on expression, and the like.Type: ApplicationFiled: May 26, 2011Publication date: October 13, 2011Inventors: Stanley N. Cohen, Limin Li
-
Patent number: 7973130Abstract: TSG101 is a tumor susceptibility gene whose homozygous functional knock out in fibroblasts leads to transformation and the ability of these cells to form metastatic tumors in nude mice. The cellular transformation that results from inactivation of TSG101 is reversible by restoration of TSG101 function. Decreased expression of TSG101 is associated with the occurrence of certain human cancers, including breast carcinomas. The TSG101 nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as treatment of cancer, identification of cell type based on expression, and the like.Type: GrantFiled: October 29, 2003Date of Patent: July 5, 2011Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Stanley N. Cohen, Limin Li
-
Patent number: 7838252Abstract: Methods and compositions for treating a subject for an anthrax toxin mediated disease condition are provided. Aspects of the subject methods include administering to a subject an effective amount of an agent that inhibits cellular internalization of an anthrax toxin, e.g., such as a LRP6 modulatory agent. Also provided are active agents suitable for use in the subject methods, as well as pharmaceutical preparations thereof.Type: GrantFiled: February 16, 2006Date of Patent: November 23, 2010Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Stanley N. Cohen, Wensheng Wei
-
Publication number: 20100272728Abstract: The present invention provides methods and compositions for regulating ubiquitination in a cell. In particular, the present invention provides purified polypeptides comprising an ubiquitination-regulating domain. The invention also provides methods of using such polypeptides for screening for agents, for producing antibodies, and for treatment of diseases, e.g., proliferative diseases, neurodegenerative diseases, autoimmune diseases, metabolic disease and developmental abnormalities. The invention further provides antibodies that bind an ubiquitination-regulating domain and agents and antibodies that regulate ubiquitination in cells, e.g., by modulating the interaction between a TSG101 protein and an MDM2 protein.Type: ApplicationFiled: March 11, 2010Publication date: October 28, 2010Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Limin Li, Stanley N. Cohen
-
Publication number: 20100272729Abstract: The present invention provides methods and compositions for regulating ubiquitination in a cell. In particular, the present invention provides purified polypeptides comprising an ubiquitination-regulating domain. The invention also provides methods of using such polypeptides for screening for agents, for producing antibodies, and for treatment of diseases, e.g., proliferative diseases, neurodegenerative diseases, autoimmune diseases, metabolic disease and developmental abnormalities. The invention further provides antibodies that bind an ubiquitination-regulating domain and agents and antibodies that regulate ubiquitination in cells, e.g., by modulating the interaction between a TSG101 protein and an MDM2 protein.Type: ApplicationFiled: March 11, 2010Publication date: October 28, 2010Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: LIMIN LI, Stanley N. Cohen
-
Patent number: 7714108Abstract: The present invention provides methods and compositions for regulating ubiquitination in a cell. In particular, the present invention provides purified polypeptides comprising an ubiquitination-regulating domain. The invention also provides methods of using such polypeptides for screening for agents, for producing antibodies, and for treatment of diseases, e.g., proliferative diseases, neurodegenerative diseases, autoimmune diseases, metabolic disease and developmental abnormalities. The invention further provides antibodies that bind an ubiquitination-regulating domain and agents and antibodies that regulate ubiquitination in cells, e.g., by modulating the interaction between a TSG101 protein and an MDM2 protein.Type: GrantFiled: January 18, 2002Date of Patent: May 11, 2010Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Limin Li, Stanley N. Cohen
-
Patent number: 7592154Abstract: Compositions and methods are provided for the use of SOS pathway targeted agents in antimicrobial formulations. The innate sensitivity of bacteria to antibiotics is increased by disrupting a mechanism that normally activates the bacterial SOS response or by inhibiting steps in the SOS response pathway itself. SOS response induction can result from exposure of bacteria to certain antibiotics, including ?-lactam antibiotics and other agents that affect cell wall synthesis. By transiently delaying bacterial cell division, SOS response induction interferes with bacterial killing by ordinarily lethal concentrations of these drugs A pharmaceutical composition comprising an SOS targeted agent is administered to a patient suffering from a microbial infection, in combination with an antibiotic that induces an SOS response.Type: GrantFiled: August 1, 2006Date of Patent: September 22, 2009Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Christine A. Miller, Ronen Mosseri, Stanley N. Cohen